Management of patients with anti-Cartwright (Yta)

Kala Mohandas, M. Spivack, C. L. Delehanty

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Five patients with anti-Cartwright (Yt(a)) in their serum were observed during a 14-month period. One of the patients in whom a 51Cr-labeled donor red cell survival study was done showed increased destruction of infused Yt(a)-positive red cells while three other patients tested showed a survival of greater than 85 percent at 1 hour. None of the antibodies potentiated interaction between sensitized red cells and heterologous activated mononuclear cells. The fifth patient recieved many transfusions of Yt(a)-positive red cells without any adverse reaction. Performance of a 1-hour red cell survival with 15Cr-labeled Yt(a)-positive cells is recommended when time permits to determine whether patients with anti-Yt(a) can receive Yt(a)-positive red cells or, alternatively, whether they must receive Yt(a)-negative red cells. This approach not only is the safest for the patient, but allows conservation of Yt(a)-negative blood. Such an approach also should be used in patients with antibodies against other high-incidence antigens.

Original languageEnglish (US)
Pages (from-to)381-384
Number of pages4
JournalTransfusion
Volume25
Issue number4
StatePublished - 1985

Fingerprint

Cell Survival
wyosine
Antibodies
Tissue Donors
Antigens
Survival
Incidence
Serum

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Mohandas, K., Spivack, M., & Delehanty, C. L. (1985). Management of patients with anti-Cartwright (Yta). Transfusion, 25(4), 381-384.

Management of patients with anti-Cartwright (Yta). / Mohandas, Kala; Spivack, M.; Delehanty, C. L.

In: Transfusion, Vol. 25, No. 4, 1985, p. 381-384.

Research output: Contribution to journalArticle

Mohandas, K, Spivack, M & Delehanty, CL 1985, 'Management of patients with anti-Cartwright (Yta)', Transfusion, vol. 25, no. 4, pp. 381-384.
Mohandas K, Spivack M, Delehanty CL. Management of patients with anti-Cartwright (Yta). Transfusion. 1985;25(4):381-384.
Mohandas, Kala ; Spivack, M. ; Delehanty, C. L. / Management of patients with anti-Cartwright (Yta). In: Transfusion. 1985 ; Vol. 25, No. 4. pp. 381-384.
@article{b0f0c042d6804722a438f64b2ede775c,
title = "Management of patients with anti-Cartwright (Yta)",
abstract = "Five patients with anti-Cartwright (Yt(a)) in their serum were observed during a 14-month period. One of the patients in whom a 51Cr-labeled donor red cell survival study was done showed increased destruction of infused Yt(a)-positive red cells while three other patients tested showed a survival of greater than 85 percent at 1 hour. None of the antibodies potentiated interaction between sensitized red cells and heterologous activated mononuclear cells. The fifth patient recieved many transfusions of Yt(a)-positive red cells without any adverse reaction. Performance of a 1-hour red cell survival with 15Cr-labeled Yt(a)-positive cells is recommended when time permits to determine whether patients with anti-Yt(a) can receive Yt(a)-positive red cells or, alternatively, whether they must receive Yt(a)-negative red cells. This approach not only is the safest for the patient, but allows conservation of Yt(a)-negative blood. Such an approach also should be used in patients with antibodies against other high-incidence antigens.",
author = "Kala Mohandas and M. Spivack and Delehanty, {C. L.}",
year = "1985",
language = "English (US)",
volume = "25",
pages = "381--384",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Management of patients with anti-Cartwright (Yta)

AU - Mohandas, Kala

AU - Spivack, M.

AU - Delehanty, C. L.

PY - 1985

Y1 - 1985

N2 - Five patients with anti-Cartwright (Yt(a)) in their serum were observed during a 14-month period. One of the patients in whom a 51Cr-labeled donor red cell survival study was done showed increased destruction of infused Yt(a)-positive red cells while three other patients tested showed a survival of greater than 85 percent at 1 hour. None of the antibodies potentiated interaction between sensitized red cells and heterologous activated mononuclear cells. The fifth patient recieved many transfusions of Yt(a)-positive red cells without any adverse reaction. Performance of a 1-hour red cell survival with 15Cr-labeled Yt(a)-positive cells is recommended when time permits to determine whether patients with anti-Yt(a) can receive Yt(a)-positive red cells or, alternatively, whether they must receive Yt(a)-negative red cells. This approach not only is the safest for the patient, but allows conservation of Yt(a)-negative blood. Such an approach also should be used in patients with antibodies against other high-incidence antigens.

AB - Five patients with anti-Cartwright (Yt(a)) in their serum were observed during a 14-month period. One of the patients in whom a 51Cr-labeled donor red cell survival study was done showed increased destruction of infused Yt(a)-positive red cells while three other patients tested showed a survival of greater than 85 percent at 1 hour. None of the antibodies potentiated interaction between sensitized red cells and heterologous activated mononuclear cells. The fifth patient recieved many transfusions of Yt(a)-positive red cells without any adverse reaction. Performance of a 1-hour red cell survival with 15Cr-labeled Yt(a)-positive cells is recommended when time permits to determine whether patients with anti-Yt(a) can receive Yt(a)-positive red cells or, alternatively, whether they must receive Yt(a)-negative red cells. This approach not only is the safest for the patient, but allows conservation of Yt(a)-negative blood. Such an approach also should be used in patients with antibodies against other high-incidence antigens.

UR - http://www.scopus.com/inward/record.url?scp=0022363896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022363896&partnerID=8YFLogxK

M3 - Article

C2 - 4024238

AN - SCOPUS:0022363896

VL - 25

SP - 381

EP - 384

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 4

ER -